Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-119323
Filing Date
2025-12-08
Accepted
2025-12-08 16:30:27
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 19685
2 EXHIBIT 99.1 tm2532979d1_ex99-1.htm EX-99.1 8133
  Complete submission text file 0001104659-25-119323.txt   29603
Mailing Address 300 FIFTH AVENUE WALTHAM MA 02451
Business Address 300 FIFTH AVENUE WALTHAM MA 02451 617-430-5595
CRESCENT BIOPHARMA, INC. (Subject) CIK: 0001253689 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-87811 | Film No.: 251556467
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428
Business Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 267-262-5300
Fairmount Funds Management LLC (Filed by) CIK: 0001802528 (see all company filings)

EIN.: 364841215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A